摘要
目的:探讨埃索美拉唑三联疗法治疗幽门螺杆菌(Hp)相关性胃溃疡的疗效。方法:采用回顾性研究方法,72例Hp相关性胃溃疡患者根据治疗方案的不同分为研究组和对照组两组,对照组患者给予奥美拉唑、莫西沙星、阿莫西林/克拉维酸钾治疗,研究组患者给予埃索美拉唑、莫西沙星、阿莫西林/克拉维酸钾治疗。两组疗程均为3周。观察两组患者治疗前后血清炎症因子水平变化;比较两组患者治疗前后临床症状评分平均值、Hp根除率、不良反应发生率、溃疡临床症状改善情况及临床疗效。结果:治疗后,两组患者的血清C反应蛋白、白细胞介素6水平以及临床症状评分平均值均较治疗前显著降低(P<0.05),且研究组各项结果均低于对照组(P<0.05)。研究组患者的Hp根除率、临床症状改善的总有效率、临床疗效总有效率均显著高于对照组(P<0.05),两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:埃索美拉唑三联疗法治疗Hp相关性胃溃疡疗效显著,Hp根除率高,能有效改善患者临床症状,降低血清炎症因子水平,且安全性高,适合临床推广应用。
Objective:To study the effcacy of esomeprazole triple therapy on the treatment of helicobacter pylori (Hp) associated gastric ulcer. Methods:Retrospective study method was used,72 cases of patients with Hp associated gastric ulcer were selected and derided into two groups according to different treatment, the control group were treated withomeprazole, moxifioxacin, amoxicillin/clavulanate potassium, the study group were treated with esomeprazole, moxifloxacin, amoxicillin / clavulanate potassium. The course of two groups were 3 weeks both. The serum levels of inflammatory cytokines were observed, the average clinical symptom scores , Hp eradication rate , the incidence of adverse reactions, improvement of ulcers clinical symptoms and clinical efficacy of the two groups before and after treatment were compared. Results: The C- reactive protein, interleukin-6 levels and the average clinical symptom scores of the two groups were signifi- cantly lower afer treatment than before (P 〈 0.05 ), and all the results of the study group were significantly lower than the control group ( P 〈 0.05) .Hp eradication rate, gastrointestinal symptoms improve overall efficiency, the clinical efficacy of the total efficiency of the study group patients were significantly higher than the control group ( P 〈 0.05 ). There had no statistical significance in the incidence of adverse drug reactions between the two groups ( P 〉 0.05 ). Conclusion: The efficacy of Hp associated gastric ulcer patients with esomeprazole triple therapy was significant, it had high Hp eradication rate, could improve the clinical symptoms and reduce the serum levels of inflammatory cytokines, and it was safe and reliable for long-term clinical application.
出处
《药物流行病学杂志》
CAS
2015年第9期529-532,共4页
Chinese Journal of Pharmacoepidemiology
关键词
幽门螺杆菌相关性胃溃疡
埃索美拉唑
三联疗法
疗效
Helicobacter pylori associated gastric uleer
Esomeprazole
Triple therapy
Efficacy